EFFICACY AND SAFETY OF ALIROCUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDY

Inadequate control of cardiovascular (CV) risk is common in patients with heterozygous familial hypercholesterolemia (HeFH), or in non-FH patients at high CV risk, with low-density lipoprotein cholesterol (LDL-C) not at target despite maximally tolerated dose (MTD) statin ± other lipid lowering